EPCAM and prostate cancer: Expression of EpCAM on non-small cell lung, breast, rectal, ovarian, prostate cancer DTCs [176, 317, 320–324]EpCAM-positive DTCs as therapeutic targets [323]Frequent loss of EpCAM expression on bone marrow-resident DTCs in esophageal cancer patients [10]